ImportantUpdates
Astec LifeSciences achieved FY26 EBITDA break-even, with ₹453.22 Cr income and reduced losses to ₹(80.88) Cr.
Astec LifeSciences LimitedASTEC · Filed with the exchange
Gross margin improved to 33.4%. CDMO revenue was ₹235 Cr.
A ₹249.35 Cr Rights Issue strengthened capital.
Company invests in R&D; Labour Code changes impacted P&L.
No comments yet. Be the first.